• If you are wondering whether BioMarin Pharmaceutical shares are attractively priced right now, you are not alone, especially with mixed signals coming through on the stock and its fundamentals.
• The share price closed at US$60.35, with returns of 1.5% over the last week, 12.3% over the last month, 1.5% year to date, but an 11.7% decline over 1 year, a 46.9% decline over 3 years, and a 25.8% decline over 5 years, which may affect how you think about risk and potential reward.
• Recent news coverage around BioMarin has focused on its rare disease treatment portfolio and ongoing regulatory and pipeline milestones. These factors often shape how investors think about long term prospects and risk, and can help explain why sentiment may shift even when the share price has been under pressure over multi year periods.
• On our valuation checks, BioMarin scores 3 out of 6 for value, as shown in our valuation score. Next, we will run through the standard valuation approaches investors often rely on, then finish with a framework that can help you put those numbers in a broader context.

Approach 1: BioMarin Pharmaceutical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value.

For BioMarin Pharmaceutical, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow sits at about $797.9 million. Based on analyst input and extrapolations, Simply Wall St projects free cash flow reaching $1.4b in 2030, with a series of annual projections between 2026 and 2035 that range from $1,038 million to $1,718.4 million before discounting.

When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of $170.74 per share. Compared with the recent share price of $60.35, this suggests that, within this DCF framework, the stock is 64.7% undervalued.

On this model alone, the market price sits well below the cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioMarin Pharmaceutical is undervalued by 64.7%. Track this in your watchlist or portfolio, or discover 872 more undervalued stocks based on cash flows.

Approach 2: BioMarin Pharmaceutical Price vs Earnings

For a profitable company like BioMarin Pharmaceutical, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings. It connects the share price directly to the earnings the business is already generating, which many investors use as a starting point when comparing opportunities.

What counts as a normal or fair P/E often reflects how the market views growth prospects and risk. Higher expected earnings growth or lower perceived risk can support a higher P/E, while slower growth or higher uncertainty can point to a lower P/E as reasonable.

BioMarin currently trades on a P/E of 22.28x. That is above the peer group average of 20.21x and also above the broader Biotechs industry average of 21.41x. Simply Wall St also calculates a Fair Ratio of 23.36x, which is the P/E they would expect for BioMarin after accounting for factors such as its earnings growth profile, industry, profit margins, market cap and key risks.

The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for BioMarin specific fundamentals rather than assuming every biotech should trade on the same multiple. Compared with the current P/E of 22.28x, the Fair Ratio of 23.36x suggests the shares look slightly undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your BioMarin Pharmaceutical Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St, that is through Narratives, which let you set out your own story for BioMarin Pharmaceutical by linking assumptions about future revenue, earnings and margins to a forecast, a fair value, and a clear comparison with the current price. All of this is housed in the Community page, where Narratives are updated as new earnings or news are released. One investor might build a Narrative around the higher fair value of about US$96.59 per share using assumptions close to the current analyst consensus. Another might anchor on the lower end of US$60.00 with more cautious views on competition and margins. You can see both side by side to decide which story, and which fair value, best fits your own expectations.

Do you think there's more to the story for BioMarin Pharmaceutical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.